^
Association details:
Biomarker:BCL2 rearrangement
Cancer:Lymphoma
Drug Class:CAR-T immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

218 - Double-Hit Lymphomas Predictive of Earlier Relapse after CAR T-Cell Therapy

Published date:
01/13/2021
Excerpt:
All patients with aBCL who received CAR-T... Pathologic confirmation of DHL was ascertained by FISH analysis of c-myc, bcl-2 and/or bcl-6 rearrangements….ORR of the entire cohort was 79%. Of the 14 DHL patients: 11 (79%) responded (CR=7, PR=4), 8 ultimately relapsed and 9 died. Univariate and multivariate regression cox analysis illustrated that DHL was the only independent factor predictive of earlier relapse (OR 5.78, P<0.005) (Table 1). No correlation of DHL and OS was observed and time from relapse to death was comparable between groups.